FNAM — Evolutionary Genomics Income Statement
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro Cap
- $0.00m
- $9.03m
Annual income statement for Evolutionary Genomics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.115 | 0.123 | 0.013 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 0.952 | 0.898 | 2.82 | 2.79 | 2.01 |
| Operating Profit | -0.837 | -0.775 | -2.81 | -2.79 | -2.01 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -1.1 | -0.761 | -2.7 | -2.79 | -1.93 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -1.1 | -0.793 | -1.71 | -2.79 | -1.93 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -1.1 | -0.793 | -1.71 | -2.79 | -1.93 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1.34 | -1.06 | -2 | -3.08 | -2.25 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.228 | -0.181 | -0.348 | -0.538 | -0.348 |